Abstract Volume:4 Issue-10 Year-2016 Original Research Articles
|Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : firstname.lastname@example.org
2General Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Chronic infection with hepatitis C virus is a global health problem that can lead to cirrhosis, liver disease and liver cancer. One of the standard treatments for hepatitis C genotype 1 is using Peginterferon and Ribavirin for 48 weeks which is associated with different complications. The aim of this study was to determine the side effects and complications due to combination therapy of interferon alpha 2b + Ribavirin in patients with Chronic Hepatitis C. In a descriptive study at the infectious diseases department at the University of Medical Sciences on patients with Chronic hepatitis C treated with Interferon-alpha 2b And Ribavirin, side effects and complications in the combination therapy of interferon alpha 2b + Ribavirin in patients with chronic hepatitis were studied. In this study, 92 patients with hepatitis c Genotype 1b were selected and studied in terms of the rate of side effects and complications of combination therapy with interferon alpha 2b + Ribavirin. 45 cases (48.9%) were male and 47 cases (51.1%) were female. The mean age of patients was 11.10 ±38.01 years. The mean ALT in patients before and 8 weeks after treatment, was dropped by 69.58 ± 54.03 and 38.48 ± 39.92, respectively and the mean AST in patients before and 8 weeks after treatment, 49.88 ± 33.84 and 34.17 ± 30.22 respectively. The mean number of WBC in patients before and 8 weeks after treatment was 6.37 ± 2.34 And 4.00 ± 1.59 respectively. The mean number of RBC in patients before and 8 weeks after treatment was 4.63 ± 0.70 and 3.74 ± 0.48 respectively. The mean number of platelets in patients before and 8 weeks after treatment was 237.01 ± 89.86 and 198.14 ± 96.63 thousand respectively. Post-treatment complications in patients under study included lethargy, Myalgia, bone pain and fever, cough and fever, loss of appetite, sleep disorders, depression and anxiety. There was a significant decrease in the levels of ALT, AST, number of WBC, RBC and platelets after treatment (P<0.001), however, there were no significant changes during the follow-up to 48 weeks (P<0.001).